Siegfried Martin M.
- Country
- Germany
- Department
- Neurologische Klinik der Ruhr-Universität Bochum
Research Overview
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
- Evaluation of Long-Term Safety and Tolerability of Tavapadon in Patients with Parkinson's Disease: A 58-Week Open-Label Multinational Study
- Efficacy and Safety Evaluation of BIIB122 in a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study in Parkinson's Disease Patients
Data & Insights
Has run more than one trial at 165 of 267 partner sites.
Specializations
Multiple Sclerosis and Neuroimmunology
Clinical research activity centers on multiple sclerosis, including relapsing, progressive, and pediatric forms, as well as clinically isolated syndrome and spasticity. The portfolio also includes related immune-mediated neurological disorders such as chronic inflammatory demyelinating polyneuropathy, myelin oligodendrocyte glycoprotein antibody-associated disease, and autoimmune encephalitis.
- Relapsing multiple sclerosis
- Primary progressive multiple sclerosis
- Progressive multiple sclerosis
- Chronic inflammatory demyelinating polyneuropathy
The therapeutic focus extends to disease-modifying strategies for disability progression and immune-mediated neurological dysfunction.
Movement Disorders and Neurodegenerative Disease
Research involvement includes Parkinson's disease, multiple system atrophy, and Huntington's disease, with attention to both early and advanced neurodegenerative presentations. Additional interest is seen in mild cognitive impairment and Alzheimer's disease, reflecting a broad neurological profile across degenerative and cognitive disorders.
- Parkinson's disease
- Multiple system atrophy
- Huntington's disease
- Alzheimer's disease
Therapeutic activity in this area includes interventions aimed at symptom control, functional preservation, and slowing neurological decline.
Autoimmune Skin Disease and Inflammatory Dermatology
A major area of interest is hidradenitis suppurativa, alongside atopic dermatitis, cutaneous lupus erythematosus, chronic spontaneous urticaria, prurigo nodularis, and vitiligo. The research landscape also includes actinic keratosis and ulcerative pyoderma gangrenosum, indicating strong engagement with inflammatory and immune-mediated skin disease.
- Hidradenitis suppurativa
- Atopic dermatitis
- Cutaneous lupus erythematosus
- Chronic spontaneous urticaria
This therapeutic domain is closely aligned with novel immunomodulatory and dermatologic treatment approaches.
Neuromuscular and Peripheral Nerve Disorders
Clinical trial involvement extends to generalized myasthenia gravis, myasthenia gravis, and inflammatory demyelinating polyneuropathy, with additional interest in chronic pain linked to peripheral and central neuropathic conditions. The portfolio also touches on post-COVID-19 postural orthostatic tachycardia syndrome, broadening the neurological and autonomic spectrum of care.
- Generalized myasthenia gravis
- Peripheral neuropathy
- Chronic neuropathic pain
- Post-COVID-19 postural orthostatic tachycardia syndrome
The therapeutic emphasis is on immune-targeted treatment for neuromuscular weakness and neuropathic symptom burden.
Acute Neurology and Headache Disorders
Research activity includes acute ischemic stroke in the setting of direct oral anticoagulant exposure and migraine in pediatric and acute-care contexts. This area reflects interest in urgent neurological treatment decisions and symptom relief across vascular and headache disorders.
- Acute ischemic stroke
- Direct oral anticoagulant
- Migraine
- Pediatric headache
The therapeutic scope includes restoration of neurological function and management of disabling headache syndromes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.